Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market, By Type (Acute ITP, Chronic ITP, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Market Analysis and Size
The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is expected to witness significant growth during the forecast period. Growing cases of blood immune disorders drives the idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of idiopathic thrombocytopenic purpura (Immune Thrombocytopenic Purpura) treatment drugs market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market in the forecast period 2022-2029. The expected CAGR of global idiopathic thrombocytopenic purpura (Immune Thrombocytopenic Purpura) treatment drugs market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 559.33 million in 2021, and it would grow upto USD 891.5 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Idiopathic thrombocytopenic purpura is the type of immune disorder in which blood does not clot normally. It is also known as immune thrombocytopenic purpura. Platelets which are produced in the bone marrow helps in the clotting function and prevent us from the excessive bleeding. It can cause excessive bruising and bleeding and form purple bruises on the skin or mucous membrane inside the mouth. Symptoms include bruising, prolonged bleeding from cuts & wounds, blood in the stools & urine and others.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute ITP, Chronic ITP, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Dynamics
Drivers
- Prevalence of Idiopathic Thrombocytopenic Purpura
The occurrence of cases of idiopathic thrombocytopenic purpura boosts the growth of the market. As per the European Medicines Agency (EMEA) records, the incidence rate of ITP rise high to 1.6 to 3.9 cases per 100,000 per year in Europe. This boosts the market growth.
- Growing Demand For Combination Therapies
The rising demand for combination therapies is expected to boost the market growth of the idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs. Studies showed that combination therapies have relatively lower side effects, and are cost-effective, and show higher response rates in patients. Some major combination therapies include rituximab and dexamethasone, corticosteroids and IVIG, TPO-RA (eltrombopag), and dexamethasone.
Opportunities
- Increased Potential Commercialization
The potential commercialization of new products such as avatrombopag by Eisai and IVIG3I 10% by Grifols, is surely boosting the market growth. Avatrombopag has showed positive clinical trial results and is expected to benefit patients with a second line of treatment upon commercialization. This creates more opportunity for the market growth.
- Increasing Demand for Retail Pharmacies
Rise in the number of drugs for idiopathic thrombocytopenic purpura being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Treatments
There are various side-effects associated with the treatment options of idiopathic thrombocytopenic purpura. Treatments such as Splenectomy have side effects such as bleeding, blood clots, bleeding, infection. Excessive use of corticosteroids can also lead to side effects such as vomiting, nausea and many others. Thus, this hampers the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Scope
The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute ITP
- Chronic ITP
- Others
Treatment
- Medication
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Regional Analysis/Insights
The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market throughout the forecasted period due to enhanced prevalence of iron deficiency anaemia and related disorders and number of generic drugs.
North America dominates the market due to increased presence of key manufacture of the product.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Share Analysis
The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market.
Key players operating in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
SKU-